Position in ABBV
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$405,140
+$45,630 QoQ
Shares Held
1,610
-2.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#3,365
of 4,153 holders
Holding Since
Mar 2022
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Capital Investment Counsel, Inc holds $4,343,317 across 8 Drug Manufacturers - General names. ABBV ranks #4 (9.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
984 | $1,180,239 | |
| 2 | JNJ |
Johnson & Johnson
|
3,798 | $964,578 | |
| 3 | AMGN |
Amgen Inc
|
1,994 | $722,067 | |
| 4 | ABBV |
AbbVie Inc.
This page
|
1,610 | $405,140 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
5,713 | $329,183 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
2,050 | $258,997 | |
| 7 | PFE |
Pfizer Inc
|
10,372 | $249,757 | |
| 8 | MRK |
Merck & Co., Inc.
|
1,816 | $233,356 |
All Filings in ABBV
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $405,140 | 1,610 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $359,510 | 1,653 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $371,296 | 1,625 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $376,252 | 1,625 | Shares | Sole | 2025-10-31 | |
| 2025-06-30 | $385,903 | 2,079 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $220,834 | 1,054 | Shares | Sole | 2025-04-28 | |
| 2024-09-30 | $262,450 | 1,329 | Shares | Sole | 2024-10-22 | |
| 2024-06-30 | $216,115 | 1,260 | Shares | Sole | 2024-07-22 | |
| 2024-03-31 | $229,446 | 1,260 | Shares | Sole | 2024-05-01 | |
| 2022-06-30 | $201,099 | 1,313 | Shares | Sole | 2022-07-22 | |
| 2022-03-31 | $206,203 | 1,272 | Shares | Sole | 2022-05-02 | |
| No filing history on record for this holder in this stock. | ||||||